Literature DB >> 27503657

In Vitro Activity of 3-Triazeneindoles against Mycobacterium tuberculosis and Mycobacterium avium.

Boris V Nikonenko1, Albert Kornienko2, Konstantin Majorov3, Pavel Ivanov2, Tatiana Kondratieva3, Maria Korotetskaya3, Alexander S Apt4, Elena Salina5, Valeriya Velezheva6.   

Abstract

Among 230 target-synthesized indole-based compounds, seven 3-triazenoindoles showed MICs of 0.2 to 0.5 μg/ml against Mycobacterium tuberculosis strain H37Rv and isoniazid-resistant human isolate CN-40. The TU112 compound was active also against a dormant form of M. tuberculosis Some of these triazenoindoles were active against Mycobacterium avium, with MICs of 0.05 to 0.5 μg/ml. The selectivity indices (SI) for M. tuberculosis and M. avium were significantly higher than 10, making these compounds acceptable for the next testing step.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27503657      PMCID： PMC5038256          DOI： 10.1128/AAC.00998-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

1.  Search for new drugs for treatment of tuberculosis.

Authors:  I Orme
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

2.  New 2-thiopyridines as potential candidates for killing both actively growing and dormant Mycobacterium tuberculosis cells.

Authors:  Elena Salina; Olga Ryabova; Arseny Kaprelyants; Vadim Makarov
Journal:  Antimicrob Agents Chemother       Date:  2013-10-14       Impact factor: 5.191

3.  Identification of SQ609 as a lead compound from a library of dipiperidines.

Authors:  Elena Bogatcheva; Colleen Hanrahan; Boris Nikonenko; Gladys de los Santos; Venkata Reddy; Ping Chen; Francis Barbosa; Leo Einck; Carol Nacy; Marina Protopopova
Journal:  Bioorg Med Chem Lett       Date:  2011-07-14       Impact factor: 2.823

4.  Rapid, simple in vivo screen for new drugs active against Mycobacterium tuberculosis.

Authors:  Boris V Nikonenko; Rowena Samala; Leo Einck; Carol A Nacy
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

5.  In vitro antimicrobial activities of capuramycin analogues against non-tuberculous mycobacteria.

Authors:  Tia Dubuisson; Elena Bogatcheva; Manju Y Krishnan; Michael T Collins; Leo Einck; Carol A Nacy; Venkata M Reddy
Journal:  J Antimicrob Chemother       Date:  2010-10-14       Impact factor: 5.790

6.  Preliminary structure-activity relationships and biological evaluation of novel antitubercular indolecarboxamide derivatives against drug-susceptible and drug-resistant Mycobacterium tuberculosis strains.

Authors:  Oluseye K Onajole; Marco Pieroni; Suresh K Tipparaju; Shichun Lun; Jozef Stec; Gang Chen; Hendra Gunosewoyo; Haidan Guo; Nicole C Ammerman; William R Bishai; Alan P Kozikowski
Journal:  J Med Chem       Date:  2013-05-03       Impact factor: 7.446

7.  Host genetics in granuloma formation: human-like lung pathology in mice with reciprocal genetic susceptibility to M. tuberculosis and M. avium.

Authors:  Elena Kondratieva; Nadya Logunova; Konstantin Majorov; Mikhail Averbakh; Alexander Apt
Journal:  PLoS One       Date:  2010-05-06       Impact factor: 3.240

8.  Novel pyridazino[4,3-b]indoles with dual inhibitory activity against Mycobacterium tuberculosis and monoamine oxidase.

Authors:  Valeriya S Velezheva; Patrick J Brennan; Vladimir Yu Marshakov; Dmitrij V Gusev; Inessa N Lisichkina; Alexander S Peregudov; Larisa N Tchernousova; Tatiana G Smirnova; Sofia N Andreevskaya; Alexei E Medvedev
Journal:  J Med Chem       Date:  2004-06-17       Impact factor: 7.446

9.  Design, chemical synthesis of 3-(9H-fluoren-9-yl)pyrrolidine-2,5-dione derivatives and biological activity against enoyl-ACP reductase (InhA) and Mycobacterium tuberculosis.

Authors:  Tetiana Matviiuk; Frédéric Rodriguez; Nathalie Saffon; Sonia Mallet-Ladeira; Marian Gorichko; Ana Luisa de Jesus Lopes Ribeiro; Maria Rosalia Pasca; Christian Lherbet; Zoia Voitenko; Michel Baltas
Journal:  Eur J Med Chem       Date:  2013-10-02       Impact factor: 6.514

10.  Different innate ability of I/St and A/Sn mice to combat virulent Mycobacterium tuberculosis: phenotypes expressed in lung and extrapulmonary macrophages.

Authors:  Konstantin B Majorov; Irina V Lyadova; Tatiana K Kondratieva; Eugeny B Eruslanov; Elvira I Rubakova; Marianna O Orlova; Vladimir V Mischenko; Alexander S Apt
Journal:  Infect Immun       Date:  2003-02       Impact factor: 3.441
View more
  3 in total

1.  Structural Modifications of 3-Triazeneindoles and Their Increased Activity Against Mycobacterium tuberculosis.

Authors:  Konstantin B Majorov; Boris V Nikonenko; Pavel Yu Ivanov; Lyudmila N Telegina; Alexander S Apt; Valeria S Velezheva
Journal:  Antibiotics (Basel)       Date:  2020-06-24

2.  Antimicrobial activity of IDD-B40 against drug-resistant Mycobacterium tuberculosis.

Authors:  Md Imtiazul Islam; Hoonhee Seo; Sukyung Kim; Venkata S Sadu; Kee-In Lee; Ho-Yeon Song
Journal:  Sci Rep       Date:  2021-01-12       Impact factor: 4.379

Review 3.  Targeting Non-Replicating Mycobacterium tuberculosis and Latent Infection: Alternatives and Perspectives (Mini-Review).

Authors:  Anna Egorova; Elena G Salina; Vadim Makarov
Journal:  Int J Mol Sci       Date:  2021-12-10       Impact factor: 5.923
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.